Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on November 14, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and business updates. The call can be accessed via phone or an audio webcast on Spero's website. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Key products include SPR720 for rare pulmonary disease and tebipenem HBr for complicated urinary tract infections, both currently under development and not FDA-approved.

Positive

• Focus on high unmet medical needs in multi-drug resistant infections.
• Development of innovative therapies like SPR720 and SPR206.

Negative

• Tebipenem HBr is not FDA-approved, indicating regulatory challenges.
• Dependence on successful clinical trials for product viability.

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10020538. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

• Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
   
• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039

Media Inquiries:
Lora Grassilli, Health Media Relations
Zeno Group
lora.grassilli@zenogroup.com
646-932-3735

FAQ

When will Spero Therapeutics announce its Q3 2022 financial results?

Spero Therapeutics will announce its Q3 2022 financial results on November 14, 2022, during a conference call at 4:30 p.m. ET.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What are the main product candidates of Spero Therapeutics?

Spero Therapeutics is developing SPR720 for a rare pulmonary disease and tebipenem HBr for complicated urinary tract infections.

How can I access the Spero Therapeutics conference call?

The conference call can be accessed by dialing 1-855-327-6837 or via audio webcast on Spero's website.